Biogen Pharmachem Industries Limited (531752) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Biogen Pharmachem Industries Limited ₹0.44, price ₹0.27, upside +63.0%, quality 38 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Biogen Pharmachem Industries Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 25, 2026.
How to read this chart
60‑month range ₹0.1886 – ₹1.56 · fair‑value band ₹0.2500 – ₹0.7600 · the ₹0.2700 price screens below the ₹0.4400 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 25, 2026.
Follow Biogen Pharmachem Industries in your weekly email
Every Wednesday you see whether Biogen Pharmachem Industries is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sun Techno Overseas Limited does not have significant operations. Previously it was engaged in trading shares, mutual funds, and other investments. The company was formerly known as Wellworth Overseas Limited and changed its name to Sun Techno Overseas Limited in August 2011. Sun Techno Overseas Limited was incorporated in 1995 and is based in Rajkot, India.
Stock analysis
Biogen Pharmachem Industries Limited (531752) currently trades at ₹0.2700, while our model-based Fair Value estimate is ₹0.4400, implying the stock looks roughly 38.6% undervalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ₹1.06 per share, and 13 of the 18 models we run sit above the ₹0.2700 price.
Bear case: the Economic Profit group reads lowest at ₹0.1500, and 5 of the 18 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹0.2500 (bear) to ₹0.7600 (bull), the price of ₹0.2700 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 38/100 (below-average quality), in the Health Care sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Biogen Pharmachem Industries Limited reported revenue of ₹0 in FY2026 versus ₹21.6M in FY2022. Reported net income was ₹9.6M in FY2026.
Key figures
Market cap ₹284M (≈ $3.0M) · EPS (TTM) ₹−0.0018 · Return on assets (EBIT) 0.9% · Free cash flow ₹15.7M · Net debt ₹534K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (low confidence).
What moves the price
The share trades about 64% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Health Care peers we cover trades at −40% fair-value upside, at 63%, 531752 screens cheaper than that median.
Fair Value models
Bear ₹0.2500Fair Value ₹0.4400Bull ₹0.7600
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.25/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year (last 3 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−16.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−16.6%
Dividend (yield on the price)0.0%
Profit margin 2019 to 2023 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.0% → 31%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+13.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +9.3% a year for the price.
Compare Biogen Pharmachem Industries Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 51 stocks
Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score38 · Bottom 25%
Fair Value upside−5.6% · Below median
Profitability
Return on assets0.0% · Below median
Operating margin (TTM)0.0% · Bottom 25%
Growth and dividend
Revenue growth0.0% · Below median
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Biogen Pharmachem Industries Limited (531752) overvalued or undervalued?
As of Sep 25, 2026, our model estimates a fair value of ₹0.4400 versus a price of ₹0.2700, about +63% upside (undervalued).
What is the fair value of 531752?
Our model-based fair value for Biogen Pharmachem Industries Limited is ₹0.4400 (as of Sep 25, 2026), built from audited fundamentals. The current price: ₹0.2700.
What is the quality score of 531752?
Biogen Pharmachem Industries Limited has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biogen Pharmachem Industries Limited (531752)?
Our model-based price target is the fair value of ₹0.4400 (as of Sep 25, 2026) from 18 valuation models. Cautious scenario ₹0.2500, optimistic scenario ₹0.7600. It is a calculation from audited fundamentals, not an analyst target.
What is the Biogen Pharmachem Industries Limited stock forecast for 2026?
Our models put fair value at ₹0.4400, about +63% upside versus a price of ₹0.2700 (undervalued). Cautious scenario ₹0.2500, optimistic scenario ₹0.7600. The calculation is refreshed regularly with new filings.
What growth is priced into Biogen Pharmachem Industries Limited (531752)?
For today's price to be fair in a discounted-cash-flow model, Biogen Pharmachem Industries Limited would have to grow free cash flow by +13.8 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew -8.5 % per year. As of Sep 25, 2026.
What discount rate (WACC) does the fair value of 531752 use?
Our models discount Biogen Pharmachem Industries Limited at 12.4 %: a base by market capitalisation (nano), country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Biogen Pharmachem Industries Limited that is +13.8 % per year a year over ten years, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has Biogen Pharmachem Industries Limited (531752) delivered so far?
Over the past 4 years revenue at Biogen Pharmachem Industries Limited grew -8.5 % a year. The price currently implies +13.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Biogen Pharmachem Industries Limited (531752) growing?
The median revenue growth in the sector is +8.1 % a year. That is the yardstick for the growth priced into Biogen Pharmachem Industries Limited (+13.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Biogen Pharmachem Industries Limited (531752)?
The free-cash-flow yield on the price is 5.52 %: that much free cash flow Biogen Pharmachem Industries Limited produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Biogen Pharmachem Industries Limited (531752)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biogen Pharmachem Industries Limited it is ₹0.4400 per share (as of Sep 25, 2026), against a price of ₹0.2700. It is the blended result of 18 valuation models (cash flow, earnings, asset, dividend).
Is Biogen Pharmachem Industries Limited stock overvalued or undervalued in 2026?
As of Sep 25, 2026, 531752 trades below its calculated fair value: price ₹0.2700, fair value ₹0.4400, a gap of about +63% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 531752?
No. The price is what the market pays today (₹0.2700); the fair value is what the company's own numbers justify (₹0.4400). For Biogen Pharmachem Industries Limited the two are ₹0.1700 per share apart. That gap is exactly why we show both numbers side by side.
How much is Biogen Pharmachem Industries Limited worth?
The market values Biogen Pharmachem Industries Limited at about ₹284M (market capitalisation, as of Sep 25, 2026). Per share that is ₹0.2700; our models calculate a fair value of ₹0.4400 per share.
What do the bullish and bearish scenarios say about 531752?
Our models span a range for Biogen Pharmachem Industries Limited: cautious scenario ₹0.2500, base ₹0.4400, optimistic ₹0.7600 per share (as of Sep 25, 2026, price ₹0.2700). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 531752 from its 52-week high?
Biogen Pharmachem Industries Limited trades at ₹0.2700, about 64% below its 52-week high of ₹0.7543 and 4% above the low of ₹0.2600 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹0.4400 is for.
Which stocks are comparable to Biogen Pharmachem Industries Limited?
From the same area (Health Care) we also value Caregen Co, ST Pharm Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biogen Pharmachem Industries Limited stock attractive at the current price?
The data as of Sep 25, 2026: price ₹0.2700, calculated fair value ₹0.4400 (+63%), Quality Score 38/100, from 18 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 531752 calculated?
We run Biogen Pharmachem Industries Limited through 18 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹0.4400, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Biogen Pharmachem Industries Limited currently trades 39 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biogen Pharmachem Industries Limited (531752)?
The closing price on Oct 1, 2026 was ₹0.2700. Our model-based fair value is ₹0.4400, about +63% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biogen Pharmachem Industries Limited right now?
The large discount to fair value meets weak quality (38/100). That raises the risk this is a value trap rather than a bargain. The model range is unusually wide (₹0.2500 to ₹0.7600). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Biogen Pharmachem Industries Limited
How large is the market capitalisation of Biogen Pharmachem Industries Limited (531752)?
The market capitalisation of Biogen Pharmachem Industries Limited is ₹284M (≈ $3.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Biogen Pharmachem Industries Limited (531752)?
Earnings per share at Biogen Pharmachem Industries Limited are ₹−0.0018. Earnings per share over the last twelve months: total profit spread across every single share.
What is the EBIT return on assets of Biogen Pharmachem Industries Limited (531752)?
On an EBIT basis the return on assets of Biogen Pharmachem Industries Limited is 0.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much net debt does Biogen Pharmachem Industries Limited (531752) carry?
The net debt of Biogen Pharmachem Industries Limited is ₹534K (fiscal year 2021, ≈ 0.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Biogen Pharmachem Industries Limited in the live analysis
One click puts Biogen Pharmachem Industries Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
